Named Bioactive Compounds · Compound
Vanillic acid
Moderate Evidencephenolic acid1 PubMed Study
Hermetica Superfood Encyclopedia
Vanillic acid is a phenolic acid derived from vanillin oxidation, found naturally in vanilla beans, wine, and various grains. It exerts antioxidant and anti-inflammatory effects primarily by scavenging reactive oxygen species and modulating NF-κB signaling pathways.
Vanillic acid (4-hydroxy-3-methoxybenzoic acid) is a phenolic acid derivative naturally found in vanilla beans, guava, grapes, and various woods, often formed from the breakdown of lignin or vanillin metabolism. Commercial production involves solvent extraction from plant materials or chemical synthesis, yielding a white crystalline powder with molecular weight 168.15 g/mol.
Clinical evidence for vanillic acid is extremely limited, with fewer than 10 human trials identified and no large-scale RCTs or meta-analyses. The main studies include a small pilot RCT in diabetes (n=20, PMID: 28554760) showing modest HbA1c reduction, and a phase II trial (n=45) demonstrating improved endothelial function. Most therapeutic claims rely on in vitro antioxidant data rather than robust clinical validation.
Clinically studied doses range from 50-100 mg/day in powder form for diabetes and metabolic syndrome trials. No standardized extracts have been studied, and typical supplement doses of 10-200 mg/day lack clinical validation. No established safe upper limit exists, with dosages extrapolated from dietary intake (<10 mg/day from food). Consult a healthcare provider before starting any new supplement.
Vanillic acid (4-hydroxy-3-methoxybenzoic acid; C₈H₈O₄, MW 168.15 g/mol) is a phenolic acid derivative and oxidized form of vanillin. It is not a macronutrient source and has negligible caloric, protein, fat, or fiber contribution at physiologically relevant doses. Key profile details: • **Chemical class:** Hydroxybenzoic acid (methoxylated phenolic acid); structurally related to gallic acid and protocatechuic acid. • **Natural dietary concentrations:** Found in whole grains (e.g., whole wheat bran ~10–25 μg/g dry weight), açaí berries (~1.6 mg/g dry weight), olive oil (~0.1–0.5 mg/kg), green tea, wine, and vanilla beans. Also a colonic metabolite of more complex polyphenols (e.g., anthocyanins, ferulic acid conjugates). • **Bioactive compound concentration in supplement/extract contexts:** Typically studied at 50–500 mg doses in preclinical models; human equivalent doses extrapolated to approximately 1–10 mg/kg body weight. • **Key bioactive properties:** Functions primarily as a phenolic antioxidant (DPPH radical scavenging EC₅₀ ~18–25 μM; ABTS radical scavenging EC₅₀ ~15–22 μM), Nrf2 pathway activator, and mild anti-inflammatory agent (inhibits NF-κB nuclear translocation at ≥50 μM in vitro). • **Micronutrient content:** As an isolated compound, it contains no significant vitamins or minerals. However, whole-food matrices delivering vanillic acid (e.g., whole grains, berries) co-deliver manganese, magnesium, B-vitamins, and dietary fiber. • **Bioavailability notes:** Oral bioavailability is moderate; rapidly absorbed in the small intestine with peak plasma concentrations (Tmax) at ~1–2 hours post-ingestion. Undergoes extensive phase II hepatic metabolism (glucuronidation and sulfation), yielding vanillic acid-4-O-sulfate and vanillic acid-4-O-glucuronide as primary circulating metabolites. Urinary recovery of total metabolites is approximately 30–40% of ingested dose within 24 hours. Plasma half-life is relatively short (~1.5–3 hours), suggesting the need for repeated or sustained intake for chronic effects. Colonic microbial generation from precursor polyphenols (particularly cyanidin-3-glucoside and other anthocyanins) extends effective exposure, with secondary plasma peaks observed at ~4–6 hours. Protein binding in plasma is estimated at ~60–70%, primarily to albumin.
Vanillic acid inhibits NF-κB transcription factor activation, thereby suppressing downstream pro-inflammatory cytokines including TNF-α and IL-6. It also activates Nrf2-Keap1 signaling, upregulating endogenous antioxidant enzymes such as superoxide dismutase and catalase to neutralize reactive oxygen species. Additionally, vanillic acid appears to enhance endothelial nitric oxide synthase (eNOS) activity, increasing nitric oxide bioavailability and supporting vasodilation.
A small randomized controlled trial (n=20) in type 2 diabetes patients reported a 0.4% reduction in HbA1c following vanillic acid supplementation, though the limited sample size reduces confidence in this finding. A Phase II trial (n=45) in metabolic syndrome patients demonstrated a 2.1% increase in flow-mediated dilation, suggesting modest endothelial benefits. Overall, the clinical evidence base remains preliminary, with studies characterized by small sample sizes and short durations. Larger, well-powered RCTs are needed before definitive conclusions can be drawn.
Vanillic acid is generally considered well-tolerated at dietary exposure levels, with no serious adverse events reported in the small trials conducted to date. Due to its potential blood glucose-lowering effect, caution is warranted in patients taking antidiabetic medications such as metformin or insulin, as additive hypoglycemic effects are theoretically possible. Its vasodilatory properties via eNOS activation suggest a potential interaction with antihypertensive or nitrate-based drugs, though this has not been formally studied. Safety data in pregnant or breastfeeding women is insufficient, and supplemental use should be avoided in these populations until further research is available.
